Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Public ClinicalTrials.gov record NCT04471428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Study identification
- NCT ID
- NCT04471428
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 366 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Cabozantinib Drug
- Docetaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2020
- Primary completion
- Sep 27, 2022
- Completion
- Jan 16, 2025
- Last update posted
- Dec 21, 2025
2020 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94305 | — |
| Kaiser Permanente - San Diego | San Diego | California | 92120 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80220 | — |
| Regional Cancer Care Associates | Bethesda | Maryland | 20817 | — |
| Minnesota Oncology Hematology | Saint Paul | Minnesota | 55102 | — |
| Consultants in Medical Oncology and Hematology | Broomall | Pennsylvania | 19008 | — |
| Charleston Oncology, P .A | Charleston | South Carolina | 29414 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Huntsman Cancer Institute at The University of Utah | Salt Lake City | Utah | 84112 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc.,-Blacksburg | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists (Fairfax) - USOR | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04471428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04471428 live on ClinicalTrials.gov.